Abstract
Introduction
Currently, the main treatment for obstructive sleep apnoea syndrome (OSAS) is a continuous positive airway pressure device (CPAP) and mandibular retaining devices (MRDs). An alternative treatment is uvulopalatopharyngoplasty (UPPP), (1) which was the dominant treatment before CPAP was generally available. In the mid-1980s when the patients in the present study were first seen, UPPP was practically the only available treatment for OSAS in Sweden. The role of UPPP has since then been questioned because of side effects and limited efficacy. In a recently published meta-analysis of 15 UPPP studies, only a 33% reduction in the apnoea-hypopnoea index (AHI) was found. (2) As there are very few randomized controlled studies, the level of evidence that UPPP can be effective as OSAS treatment is low.
Also, there are a few long-term follow-up studies after UPPP; such studies have been called for because a decreasing effect over time has been suspected. (3) The patients in the present study have previously been evaluated at 6 months, 2 and 4 years postoperatively regarding excessive daytime sleepiness (EDS) and renewed sleep apnoea recordings. (4) , (5) They showed significant decreases in the mean oxygen desaturation index of 4% (ODI 4 ), but 50% of the patients were regarded as failures (ODI 4 > 20 with reduction < 50%). Another long-term study on 34 patients by Janson et al., (6) using stricter success criteria (AHI < 10 with reduction > 50%), found that 52% were failures 4-8 years after UPPP surgery. Side effects of the UPPP, with different aspects of pharyngeal disturbances, are reported. (7) However, in a recent questionnaire study of OSAS patients at our centre, there was no increase in the median pharyngeal symptom score one year after UPPP, compared to baseline. (8) The mortality results among UPPP-treated patients have been studied by Lysdahl and Haraldsson. (9) No increased mortality was found after UPPP in a 5 to 9-year follow-up of results might indicate a positive survival effect of surgery. Otherwise, mortality studies on OSAS patients have indicated an approximately 3 times increased mortality rate. (10) , (11) The aim of the present study was to evaluate the efficacy of UPPP treatment for OSAS after 15 years, the longest follow-up hitherto. The effects were measured objectively with sleep apnoea recordings as well as subjectively with questionnaires concerning patient overall satisfaction, daytime sleepiness, pharyngeal side effects, and snoring. The mortality rates of the original group of patients were calculated in comparison to the Swedish general population. The recordings comprised respiratory and body movements, body position, ear oximetry, and sound (dB) measurements using the digitized Apnolog system (C-A Tegner Inc., Stockholm, Sweden). The oximetry and dB levels were scored using the Apnolog software. Sleeping time was manually estimated from the movement recording by one of the investigators (E.S.), who was blinded to the patient's subjective symptoms. The percentage of the estimated total sleep time (TST) during which respiratory sounds exceeded 40 dB was calculated, and if the time was above 40%, the patient was objectively classified as a snorer.
Materials and Methods

Subjects
Success criteria of sleep apnoea recordings: ODI 4 < 20 and reduction of at least 50% compared to baseline. No more than 10 desaturations below 90% during 6 hours of sleep.
Distributed questionnaires:
A. Questionnaire concerning satisfaction, EDS, and subjective snoring. The questions were: 
Ethical Considerations
All patients gave their informed consent and the study was approved by the Swedish local Ethics Committee at Huddinge University Hospital, Stockholm (474/03).
Statistics
The following non-parametric statistical methods were used: Wilcoxon-matched pair tests (WMPTs) to compare the results before and after surgery; Mann-Whitney U tests (MWUTs)
for unpaired tests of drop-out and subgroup analyses. Correlation analyses were performed using Spearman rank correlation tests (SRCTs). The software program Statistica 6.0 was used.
Standardized Mortality Ratio (SMR) Calculations:
The cohort was followed from the date of surgery up to the date of death or December 31, 2008, which ever occurred first. The expected mortality in the patient group was estimated by splitting the person years of follow-up according to the attained age in 5-year age bands and calendar years, and multiplying these by the corresponding sex-specific mortality rate in the general population. The overall and circulatory disease-specific mortality rates were obtained from the Swedish Cause of Death The questionnaires were answered by 32 of the 37 living patients (86%). Twenty-five patients (78%) were satisfied with the surgery, but four regretted it. Twenty-three patients (72%) stated that they would recommend the surgery to another person. Concerning subjective snoring, two rated "never", 11 "sometimes", 11 "often", and 8 "always". Thus 13 out of 32 (40%) rated "never" or "sometimes"; Figure 1 . Ten patients rated that they were "cured"
concerning EDS, 18 "better", and 4 patients were "unchanged" compared to baseline, thus 28 of 32 (88%) were "better" or "cured"; Figure 2 . The median ESS value was 6 (range 0-19).
The median pharyngeal disturbances value after UPPP was 3 (range 0-10).
Yes 78% In the mortality analysis we had a prolonged observation period of, in total, 18.2 years up to As reported earlier by Larsson et al., (4) , (5) The most important finding in this study is that neither the objective (sleep recordings) nor the subjective results deteriorated over time, as has been suspected. A decrease in BMI does not seem to be an explanation, since median BMI did not change. We were positively surprised that these patients kept their weight, which might be explained by our clinical practice; to inform all patients of the importance of stable weight after surgery. One reason for the positive result concerning symptoms could be that the prevalence levels of OSAS has been known to decrease in older ages,(16) at least in males, which was the predominant gender (96%) in our study population.
The efficacy role of UPPP in OSAS treatment has been questioned because there have been very few randomized studies. In a 4-year follow-up of a randomized trial of MRD and UPPP, Walker-Engström et al. concluded that the MRD group showed a significantly higher success rate regarding the apnoea index compared to the UPPP group, i.e., 81% compared to 53%, but that the effectiveness of the MRD was invalidated by the compliance rate of only 62%. (17) In the present study, there was a surprisingly high satisfaction rate and few regrets, considering the very long follow-up period, which may reflect the fact that the majority of the patients considered themselves improved in their symptoms. However, the success level for snoring was lower, but this did not seem to influence the satisfaction rating. Also, even among the patients who had complementary treatment (ISO, CPAP, or MRD), the majority were satisfied with the surgery.
The postoperative pharyngeal symptoms were few. Our group has previously evaluated the results for UPPP patients both preoperatively and postoperatively. (8) There were no increased rating of pharyngeal symptoms postoperatively, with an unchanged median value of 5.
However, in a non-snoring age-, BMI-and gender-matched control group, the median value was only 1, indicating a certain amount of discomfort already before surgery in OSAS patients. There have been reports of large proportions of dysphagia and globus sensation in UPPP patients,(7) but the surgical techniques have changed over time, making such reports confusing. In many cases a mixture of methods has been used and the reports are therefore difficult to interpret. However, at our centre, a conservative technique using cold steel with a one-stage procedure has been employed throughout the years.
The standardized mortality ratios indicated no increased mortality in this OSAS population compared to the general population in Sweden. There are several studies indicating an approximately 3 times increased mortality associated with severe untreated OSAS. (10) , (11) Our study population was heterogeneous, including all degrees of OSAS, obesity and cardiovascular comorbidity. UPPP was practically the only available treatment for OSAS at the time, and it was offered to all who did not have any major contraindication for surgery, explaining the heterogeneity in our population. The reason for our low mortality rates could be explained by the fact that several patients were treated with CPAP and MRD at least in periods if the UPPP treatment had failed, and two patients had complementary mandibular surgery. Another reason could be a protective effect of UPPP, as suggested by other authors.(9) However from our small and heterogeneous population it is difficult to draw such conclusions. In addition, Lavie et al. have suggested a protective role of having moderate OSAS at higher ages, possibly by the mechanism that apnoea during sleep may activate adaptive pathways so that chronic intermittent hypoxia may be cardioprotective. (16) There are several weaknesses in this study: firstly, the lack of a randomized control group, and, secondly, a 15-year recall bias. Thirdly, there were a relatively small number of patients who underwent the 15-year follow-up sleep apnoea recording, only 26 of the originally included 50 patients. However, the very long follow-up quite naturally explains that 11 patients did not show up and that 13 were deceased. In addition, the subgroup analyses only showed small and non-significant differences, except between the living and deceased concerning age. The deceased patients were at baseline 9 years older than the living ones, there was no washout period for the 6 patients with CPAP and one with MRD, so a remaining effect of these complementary treatments could have affected the outcomes in these patients, which could also be the case for the patient who had undergone ISO. However, the subjective outcome did not show any major differences. In the sleep apnoea recordings, the ODI 4 was higher than in the group without complementary treatment, which was expected. Other studies have shown that the majority of apnoeas relapse already during the first night without CPAP. (19) The most important strength of this study is the very long-term follow-up including sleep recordings. Furthermore, the majority of these patients have undergone four different followups over the years, which enabled us to show consistency in the results from sleep recordings.
Also, considering the time period, the drop-out rate of the subjective measurement was quite low (14%). Lastly, the Swedish social security number register makes it possible to follow the study population's mortality rates and causes and to keep updated address records.
Conclusions
This 15 year follow-up after UPPP, the longest hitherto performed, showed a stable and significant decrease in median ODI 4 values throughout the years. Objectively, approximately two thirds of the patients fulfilled the success criteria (ODI 4 reduction of 50% and < 20).
Subjectively, a vast majority had improved/cured EDS and was satisfied. No increased mortality rate was seen compared to the general Swedish population.
